Lv546
1440 积分 2023-01-06 加入
Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial
4小时前
待确认
Increasing BCI communication rates with dynamic stopping towards more practical use: an ALS study
4小时前
待确认
Brain-computer interface ( BCI ) evaluation in people with amyotrophic lateral sclerosis
4小时前
待确认
A brain-computer interface for long-term independent home use
4小时前
待确认
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
6小时前
待确认
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
6小时前
待确认
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
10小时前
待确认
HER2-Low Breast Cancer: Pathological and Clinical Landscape
1天前
待确认
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
4天前
已完结
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
7天前
已完结
皖公网安备34019202002308
